Myxoma of the femur: an unusual site of origin

Santhanam, Siva Swaminathan; Goni, Vijay; Saibaba, Balaji; Das, Ashim

doi:10.1136/bcr-2015-211480

Cited by 3 publications

(3 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These masses are recommended to be followed at 3, 6, 12, and 24 months, or until the lesion spontaneously resolves or significantly regresses. Representative masses include histiocytosis in appropriate age group, intraosseous myxoma, chondromyxoid fibroma, giant cell tumor (GCT), chondroblastoma, synovial chondromatosis with bone involvement, enchondroma protuberance in hands and feet, desmoplastic fibroma, fibrous dysplasia, Paget disease, epithelioid hemangioma, and so on 31–45 . Postcontrast imaging of such lesions usually shows variable enhancement.…”

Section: Methodsmentioning

confidence: 99%

“…Representative masses include histiocytosis in appropriate age group, intraosseous myxoma, chondromyxoid fibroma, giant cell tumor (GCT), chondroblastoma, synovial chondromatosis with bone involvement, enchondroma protuberance in hands and feet, desmoplastic fibroma, fibrous dysplasia, Paget disease, epithelioid hemangioma, and so on. [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45] Postcontrast imaging of such lesions usually shows variable enhancement. Diffusion-weighted imaging, if obtained, exhibits moderate-marked hyperintensity of the lesion on DWI and mild-moderate hyperintensity on ADC images, with generally a mean ADC value = 1.2-2.0 Â 10 −3 mm 2 /s.…”

Section: Ot-rads Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Osseous Tumor Reporting and Data System—Multireader Validation Study

Chhabra¹,

Gupta

Thakur

et al. 2021

J Comput Assist Tomogr

View full text Add to dashboard Cite

To develop and validate an Osseous Tumor Reporting and Data System (OT-RADS) with the hypothesis that the proposed guideline is reliable and assists in separating benign from malignant osseous tumors with a good area under the curve, and that could assist further patient management. Methods:In this multireader cross-sectional validation study, an agreement was reached for OT-RADS categories based on previously described magnetic resonance imaging features and consensus of expert musculoskeletal radiologists. World Health Organization classification was used, and a wide spectrum of benign and malignant osseous tumors was evaluated. Magnetic resonance imaging categories were as follows: OT-RADS 0-incomplete imaging; OT-RADS I-negative; OT-RADS IIdefinitely benign; OT-RADS III-probably benign; OT-RADS IVsuspicious for malignancy or indeterminate; OT-RADS V-highly suggestive of malignancy; and OT-RADS VI-known biopsy-proven malignancy or recurrent malignancy in the tumor bed. Four blinded readers categorized each tumor according to OT-RADS classification. Intraclass correlation (ICC) and Conger κ were used. Diagnostic performance measures including area under the receiver operating curve were reported. Osseous Tumor Reporting and Data System was dichotomized as benign (I-III) and malignant (IV and V) for calculating sensitivity and specificity.Results: Interreader agreement for OT-RADS (ICC = 0.78) and binary distinction of benign versus malignant (κ = 0.67) were good to excellent, while agreement for individual tumor feature characteristics were poor to fair (ICC = 0.25-0.36; κ = 0.16-0.39). The sensitivities, specificities, and area under the receiver operating curve of the readers ranged from 0.93-1.0, 0.71-0.86, and 0.92-0.97, respectively.Conclusions: Osseous Tumor Reporting and Data System lexicon is reliable and helps stratify tumors into benign and malignant categories. It can be practically used by radiologists to guide patient management, improve multidisciplinary communications, and potentially impact outcomes.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Ot-rads Developmentmentioning

confidence: 99%

Osseous Tumor Reporting and Data System—Multireader Validation Study

Chhabra¹,

Gupta

Thakur

et al. 2021

J Comput Assist Tomogr

View full text Add to dashboard Cite

show abstract

“…In the orofacial area, myxomas are not uncommon and mostly occur in the gnathic skeleton of the odontogenic ectomesenchyme and are very similar to mesenchymal portions of a developing tooth [3]. Odontogenic myxomas are the most common myxomas arising from hard tissue, extragnathic skeletal myxomas are very rare [4].…”

Section: Rationale -Objectivesmentioning

confidence: 99%

Juxta-articular myxoma of the temporomandibular joint: Case report and review

Goetze¹,

Agaimy²,

Kesting³

2021

Case Rep Imag Surg

View full text Add to dashboard Cite

Introduction: Juxta-articular myxoma ( JAM) is a rare benign myxoid lesion that arises predominantly in the vicinity of large joints (hence the name) with the knee joint followed much less frequently by shoulder, elbow, hip and ankle joints being the main sites affected. Involvement of the temporomandibular joint (TMJ) by JAM is exceptionally rare making this entity not well-known by oro-maxillofacial surgeons. We present a case of JAM located at the TMJ and gives a systematic review of the literature on this topic. Methods: A systematic search for "juxta-articular myxoma" " +"TMJ", "mandible" and temporomandibular" in English/French/German literature in PubMed, Medline, WebOfScience, OpenGrey and GoogleScholar was performed. The retrieved papers were then analyzed for the anatomical region, diagnostics, treatment, follow-up time and potential recurrence.Results: JAM mainly occurs at the knee, shoulder or the elbow, other locations are rare. Main diagnostic imaging for JAM is MRI-scan. Excision of the lesion is standard therapy. Local recurrence is reported in 23% for an average follow-up of 38 months. Involvement of the TMJ was reported in 1% of total cases. Conclusion:JAM is a rare benign tumor with local aggressive features. Occurrence at the mandible is quite rare. Due to the confined anatomical region of the TMJ complete removal may be difficult, a distinctive approach should be planned to guarantee optimal access. This fact and a high recurrence rate imply the need of a close follow-up.

show abstract

An Interesting Case of Intramuscular Myxoma with Scapular Bone Lysis

Tirefort

Kolo²,

Lädermann

2017

Case Reports in Orthopedics

View full text Add to dashboard Cite

Introduction. Intramuscular myxoma is a rare benign primitive tumor of the mesenchyme founded at the skeletal muscle level; it presents itself like an unpainful, slow-growing mass. Myxomas with bone lysis are even more rare; only 7 cases have been reported in the English literature, but never at the shoulder level. Case Presentation. We describe an 83-year-old patient with a growing mass in the deltoid muscle with unique scapular lysis, without any symptom. Magnetic resonance imaging (MRI) and a biopsy were performed and the diagnosis of intramuscular myxoma has been retained. In front of this diagnosis of nonmalignant lesion, the decision of a simple follow-up was taken. One year after this decision, the patient was still asymptomatic. Conclusion. In the presence of an intramuscular growing mass with associated bone lysis, intramuscular myxoma as well as malignant tumor should be evoked. MRI has to be part of the initial radiologic appraisal but biopsy is essential to confirm the diagnosis. By consensus, the standard treatment is surgical excision but conservative treatment with simple follow-up can be an option.

show abstract

Myxoma of the femur: an unusual site of origin

Cited by 3 publications

References 9 publications

Osseous Tumor Reporting and Data System—Multireader Validation Study

Osseous Tumor Reporting and Data System—Multireader Validation Study

Juxta-articular myxoma of the temporomandibular joint: Case report and review

An Interesting Case of Intramuscular Myxoma with Scapular Bone Lysis

Contact Info

Product

Resources

About